Patent intelligence · US
US 6410023
Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
Patent details — US 6410023
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jun 25, 2002
- Expiration
- Jun 20, 2022
- Applicant
- The United States of America
- Claims
- 53
- CPC classes
- A61K, A61K2039/522, A61K39/00, A61P
Quick answer
US 6410023 (Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene) is held by The United States of America. Status: expired. Granted Jun 25, 2002. Expires Jun 20, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The United States of America
- Grant date
- Expiration
- Claims
- 53
- CPC classes
- A61K, A61K2039/522, A61K39/00, A61P, A61P31/16
More from The United States of America
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 6410023?
US 6410023 (Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene) is held by The United States of America. Status: expired. Granted Jun 25, 2002. Expires Jun 20, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6410023?
The United States of America is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 6410023 expire?
Our index shows an expiration date of Jun 20, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.